Funding supports first-in-human trials for innovative heart failure fluid management system.
Breakthrough Technology for Heart Failure
Relief Cardiovascular announced the close of a $12 million Series A funding round to support a first-in-human feasibility study and continued development of its Relief System, a smart transcatheter implant designed to monitor and modulate renal vein pressures.
The Relief System offers a novel, device-driven approach to manage heart failure-related fluid overload, addressing the unmet needs of diuretic-resistant patients.
Key Features of the Relief System
- Dynamic Modulation: Utilizes a “puller” mechanism to reduce renal vein pressure.
- Integrated Sensors: Captures renal vein pressures and multiparametric data for actionable insights.
- Tailored Care: Enables personalized, data-driven fluid management for heart failure patients.
Investment and Leadership
- Funding Round Leaders: Broadview Ventures and Advent Life Sciences, alongside Pacific Health Investment, Heartwork Capital, and an undisclosed strategic partner.
- Board Appointments: Dr. Shahzad Malik (Advent Life Sciences) and Dr. Maria Berkman (Broadview Ventures) join Relief Cardiovascular’s board.
Expert Endorsements
- Dr. William T. Abraham, The Ohio State University Wexner Medical Center:
“The integration of monitoring and therapeutic modulation represents a promising advance in heart failure management.” - Dr. Alex Rothman, University of Sheffield:
“The Relief System empowers personalized care, particularly for diuretic-resistant patients.”
A New Era in Heart Failure Treatment
By providing real-time renal vein pressure data and enabling dynamic intervention, the Relief System aims to redefine fluid management, improving outcomes for patients with limited treatment options.
Follow MEDWIRE.AI for more updates on innovative cardiovascular solutions and medical technology breakthroughs.
